Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COSTEM 2019 | Can third party CMV-specific T-cells replace drug therapy?

Per Ljungman • 26 Oct 2019
COSTEM 2019
General CAR-T

Per Ljungman, MD, PhD, Karolinska University Hospital, Solna, Sweden, evaluates third-party CMV-specific T-cells replacing drug therapy. This interview took place at the 5th International Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) 2019, held in Berlin, Germany.

More from Per Ljungman

0:27
What to expect from TCT 2021?
Per Ljungman • 5 Feb 2021
5:37
Stem cell transplantation & cellular therapy during COVID-19 in Europe
Per Ljungman • 5 Feb 2021
1:30
EBMT Project 2020: migration of data
Per Ljungman • 1 Sep 2020
2:46
Letermovir prevents cytomegalovirus (CMV) in transplant patients
Per Ljungman • 24 Aug 2020

Related Videos

1:41
The consequences of regulatory changes on access to devices and reagents needed for graft processing
Christian Chabannon • 16 Apr 2024
5:23
Current and emerging treatment approaches for steroid-refractory acute & chronic GvHD
Mohamad Mohty • 17 Apr 2024
4:07
Pooled fecal allogeneic microbiotherapy to treat refractory gastrointestinal acute GvHD
Florent Malard • 11 Apr 2024
2:00
HHV-6 reactivation after haploidentical transplantation with PTCy & ATG: incidence and risk factors
Rémy Duléry • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals